Evidence map›Paper›PMID 41135096›Full record

ReviewAging and disease2025

Annexin A5 in Ischemic Stroke: Molecular Mechanisms and Translational Therapy Strategies.

Zhanwei Zhu, Jiachen He, Qi Liu, Jiaqi Guo, Jingbei Liu, Shuaili Xu, Xi Chen, Di Wu

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Aging and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Zhanwei ZhuDepartment of Neurology and China-America Institute of Neuroscience, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Jiachen HeDepartment of Neurology and China-America Institute of Neuroscience, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Qi LiuDepartment of Neurology and China-America Institute of Neuroscience, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Jiaqi GuoDepartment of Neurology and China-America Institute of Neuroscience, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Jingbei LiuDepartment of Neurology and China-America Institute of Neuroscience, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Shuaili XuBeijing Institute of Brain Disorders, Capital Medical University, Beijing 100053, China.
Xi ChenDepartment of Neurology and China-America Institute of Neuroscience, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.
Di WuDepartment of Neurology and China-America Institute of Neuroscience, Xuanwu Hospital, Capital Medical University, Beijing 100053, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Previous research has identified externalized phosphatidylserine (PS) as an "eat me" signal in apoptosis regulation. Targeting PS thus represents a promising therapeutic approach. Annexin A5, known for its high affinity for PS, has traditionally been used as a FITC-labeled probe for detecting apoptosis. Recent studies have demonstrated that Annexin A5 can cross the blood-brain barrier and selectively bind to PS-exposed injured tissues, exerting multiple protective effects, such as anticoagulant, anti-inflammatory, and anti-apoptotic actions. Furthermore, emerging evidence suggests that Annexin A5 holds potential for molecular imaging of the ischemic penumbra and for the development of lesion-targeted drug delivery systems. In summary, Annexin A5 has garnered increasing attention for its neuroprotective properties and therapeutic potential. Ischemic stroke is one of the leading causes of disability and mortality worldwide. Ischemic stroke management still requires effective neuroprotective agents and innovative imaging strategies to improve clinical outcomes. This article provides a comprehensive analysis of protective mechanisms and translational applicability of Annexin A5 in ischemic stroke therapy, offering novel insights for the development of next-generation multi-target cerebrovascular interventions.

Indexed as

Annexin A5Brain IschemiaIschemic StrokeNeuroprotective AgentsAnimalsApoptosisBlood-Brain BarrierHumansTranslational Research, BiomedicalAnnexin A5Neuroprotective Agents

Identifiers

PMID41135096
PMCPMC13653699

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.